Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
(applications tested for the base form of this product only)
Specificity and Use
CDKN2A / p16INK4a antibody was raised against the epitope recognized by this antibody maps to a region between residue 75 and 125 of human p14ARF using the numbering given in entry NP_478102.1 (GeneID 1029)
The applications listed have been tested for the unconjugated form of this product. Other forms have not been tested.
Capable of inducing cell cycle arrest in G1 and G2 phases. Acts as a tumor suppressor. Binds to MDM2 and blocks its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits the oncogenic action of MDM2 by blocking MDM2-induced degradation of p53 and enhancing p53-dependent transactivation and apoptosis. Also induces G2 arrest and apoptosis in a p53-independent manner by preventing the activation of cyclin B1/CDC2 complexes.
Detection of Human p14ARF by western blot. samples: whole cell lysate (25 ug) from BT549 positive control. U2os (negative control) and p14ARF transfected IMR90 cells. Affinity purified rabbit anti p14ARF (CDKN2A Antibody LS-C83822) used at a 1 ug/ml. This image was taken for the unconjugated form of this product. Other forms have not been tested.
Requested From: United States
Date Requested: 2/19/2017